Company Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.06 ^USD	+2.91%		+0.95%	+0.95%

Apr. 01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 26	Transcript : Quince Therapeutics, Inc. - Special Call

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patientâs own biology to deliver life-changing therapeutics to those living with rare diseases. The Companyâs asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patientâs own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The Company is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The Company also intends to investigate additional potential applications of the AIDE technology platform.

Number of employees: 32

Managers	Title	Age	Since
Dirk Thye CEO	Chief Executive Officer	54	22-05-18
Brendan Hannah DFI	Director of Finance/CFO	39	22-04-30
Charles Ryan PSD	President	60	23-08-31
Maureen M. Roden CTO	Chief Tech/Sci/R&D Officer	-	22-05-31
Stacy Roughan IRC	Investor Relations Contact	-	-
Gary Ward PRN	Corporate Officer/Principal	-	22-07-31
Mary Ellen Sillivos HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Una Ryan BRD	Director/Board Member	82	18-02-28
Luca Benatti BRD	Director/Board Member	63	23-10-22
Dirk Thye CEO	Chief Executive Officer	54	22-05-18
David Lamond CHM	Chairman	49	15-11-30
Rajiv Patni BRD	Director/Board Member	55	Feb. 14
Christopher Senner BRD	Director/Board Member	56	19-02-28
Margaret McLoughlin BRD	Director/Board Member	61	15-11-30
June Bray BRD	Director/Board Member	70	22-06-08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	43,215,233	35,841,506 ( 82.94 %)	0	82.94 %

Name	Equities	%	Valuation
David Lamond 10.23 %	4,384,096	10.23 %	5 M $
Tang Capital Management LLC 7.511 %	3,220,000	7.511 %	3 M $
Genextra SpA 5.892 %	2,525,950	5.892 %	3 M $
Sofinnova Partners SAS 5.081 %	2,178,150	5.081 %	2 M $
Casey Lynch 2.754 %	1,180,580	2.754 %	1 M $
Vanguard Global Advisers LLC 2.267 %	971,801	2.267 %	1 M $
EPIQ Capital Group LLC 2.030 %	870,133	2.030 %	922 341 $
Dirk Thye 1.608 %	689,441	1.608 %	730 807 $
Philip Low 1.211 %	519,283	1.211 %	550 440 $
Renaissance Technologies LLC 1.070 %	458,680	1.070 %	486 201 $

Quince Therapeutics, Inc.

611 Gateway Boulevard Suite 273

94080, South San Francisco

http://quincetx.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUINCE THERAPEUTICS, INC.	+0.95%	45.81M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research